Our assay improved signal integrity and revealed distinct clinical associations: specific PD-L1+ CTC phenotypes were linked to metastasis and correlated with improved immunotherapy response, whereas PD-L1+ CTECs were associated with treatment resistance and serum tumor markers. This evidence concerns the gene CD274 and neoplasm.